Literature DB >> 27072903

Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.

Soham D Puvvada1, Patrick J Stiff2, Michael Leblanc3, James R Cook4, Stephen Couban5, John P Leonard6, Brad Kahl7, Deborah Marcellus8, Thomas C Shea9, Jane N Winter10, Hongli Li3, Lisa M Rimsza1, Jonathan W Friedberg11, Sonali M Smith12.   

Abstract

Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  BCL2; MYC; autologous stem cell transplant; double hit lymphoma; double protein lymphoma

Mesh：

Substances：

Year:  2016        PMID： 27072903      PMCID： PMC5125530          DOI： 10.1111/bjh.14100

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  14 in total

1.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

2.  MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Authors:  Anamarija M Perry; Yuridia Alvarado-Bernal; Javier A Laurini; Lynette M Smith; Graham W Slack; King L Tan; Laurie H Sehn; Kai Fu; Patricia Aoun; Timothy C Greiner; Wing C Chan; Philip J Bierman; Robert G Bociek; James O Armitage; Julie M Vose; Randy D Gascoyne; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2014-02-08       Impact factor: 6.998

Review 3.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

4.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Authors:  Nathalie A Johnson; Kerry J Savage; Olga Ludkovski; Susana Ben-Neriah; Ryan Woods; Christian Steidl; Martin J S Dyer; Reiner Siebert; John Kuruvilla; Richard Klasa; Joseph M Connors; Randy D Gascoyne; Douglas E Horsman
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

5.  Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.

Authors:  Jonathon B Cohen; Susan M Geyer; Gerard Lozanski; Weiqiang Zhao; Nyla A Heerema; Nathan C Hall; Veena A Nagar; Jessica A Hemminger; Jeffrey A Jones; Pierluigi Porcu; Beth A Christian; Robert A Baiocchi; Kami J Maddocks; Joseph M Flynn; Steven M Devine; Kristie A Blum
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Authors:  Heike Horn; Marita Ziepert; Claudia Becher; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Michael Hummel; Harald Stein; Martin-Leo Hansmann; Christopher Schmelter; Peter Möller; Sergio Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Reiner Siebert; Markus Loeffler; Andreas Rosenwald; German Ott
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

8.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Authors:  Adam M Petrich; Mitul Gandhi; Borko Jovanovic; Jorge J Castillo; Saurabh Rajguru; David T Yang; Khushboo A Shah; Jeremy D Whyman; Frederick Lansigan; Francisco J Hernandez-Ilizaliturri; Lisa X Lee; Stefan K Barta; Shruthi Melinamani; Reem Karmali; Camille Adeimy; Scott Smith; Neil Dalal; Chadi Nabhan; David Peace; Julie Vose; Andrew M Evens; Namrata Shah; Timothy S Fenske; Andrew D Zelenetz; Daniel J Landsburg; Christina Howlett; Anthony Mato; Michael Jaglal; Julio C Chavez; Judy P Tsai; Nishitha Reddy; Shaoying Li; Caitlin Handler; Christopher R Flowers; Jonathon B Cohen; Kristie A Blum; Kevin Song; Haowei Linda Sun; Oliver Press; Ryan Cassaday; Jesse Jaso; L Jeffrey Medeiros; Aliyah R Sohani; Jeremy S Abramson
Journal:  Blood       Date:  2014-08-26       Impact factor: 22.113

9.  Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.

Authors:  James R Cook; Bryan Goldman; Raymond R Tubbs; Lisa Rimsza; Michael Leblanc; Patrick Stiff; Richard Fisher
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  6 in total

Review 1.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 2.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors:  Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 3.  Double-Hit Large B Cell Lymphoma.

Authors:  Yousef Khelfa; Yehuda Lebowicz; Muhammad Omer Jamil
Journal:  Curr Oncol Rep       Date:  2017-09-26       Impact factor: 5.075

4.  Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.

Authors:  Lu Li; Yanyan Li; Ximei Que; Xue Gao; Qian Gao; Mingxing Yu; Kaili Ma; Yanfeng Xi; Tong Wang
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

Review 5.  Altered pathways and targeted therapy in double hit lymphoma.

Authors:  Yuxin Zhuang; Jinxin Che; Meijuan Wu; Yu Guo; Yongjin Xu; Xiaowu Dong; Haiyan Yang
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388

6.  Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.

Authors:  Junnan Kang; Yizhuo Zhang; Sa Ding; Kalbinur Yasheng; Yueyang Li; Yong Yu; Yafei Wang; Chen Tian
Journal:  J Cell Mol Med       Date:  2021-10-25       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.